Biotech and medical device consulting firm focusing on corporate strategy, business development and portfolio optimization. Supporting biotech, pharma and device clients with business and strategic analysis in the U.S., Europe, Japan and China. Notable recent and ongoing projectsLate-Stage Neuroscience Biotech – SVP Business Development and Strategy• Driving licensing activities for portfolio of assets• Preparing company for Series C raise• Strategic advisor to CEO and BoardClinical stage oncology firm – Chief Business Officer• Focused on strategic business development opportunities and fundraising for Phase II clinical studiesCommercial Stage Drug Delivery Firm – Advisor to Board, CTO and Business Development• Leading strategy development and business development/valuation activities

Abvance is developing a titratable, fixed ratio combination of two well understood and FDA approved peptides to control glycemia while mitigating the threat of hypoglycemia. The firm is currently engaged in raising Series A funding.Led operations of firm and directed turnaround while conducting fundraising efforts to fund next phase of product development• Refocused business and strategy to better set up the firm for investment by biotech Venture Capital firms• Serve as face of the company in over 100 pitches to potential investors including VCs and Private Equity• Negotiated revised development agreements with development partners

BioShore Partners assembles drug development opportunities that leverage combinations of clinically validated bio-molecules and small molecule agents to treat an array of metabolic indications with unmet clinical needs. BioShore Partners provides a rich source of enabling technologies and access to world-class centers to conduct pre-clinical and clinical investigations to incubate and foster product concepts into new Biotech entities. Abvance Therapeutics: In collaboration with Vanderbilt University, developed intellectual property and supporting data for a novel treatment paradigm for T1DM and insulin-requiring T2DM patients, involving dual peptides in a fixed ratio - producing a simplified bionic pancreas treatment approach. Aquoros Bio Inc,: In collaboration with a thought leading urologist, developed intellectual property for a novel treatment paradigm for Interstitial Cystitis/Painful Bladder Syndrome (novel multi-drug treatment and delivery).

Our work focuses on developing novel drugs around kinases, specifically p90 ribosomal S6 kinases (RSK), which we have led the field in establishing as a molecular target for cancer.• Led Series B fund raising activities seeking $80M for phase IIB clinical trials and operations• Drove out-license of non-core assets and international rights to lead and backup molecules primarily in Asia

Medicus Biosciences, a pre-clinical private life science R&D company specializing in polymer technology. Medicus' polymers are used in a variety of therapeutic areas from advanced wound management to localized drug delivery. Lead commercial asset licensed in 3Q19.Recruited as change agent to redirect corporate strategy to retain funding and turn the company around. Reported directly to board of directors of South American private equity investor. Responsible for corporate strategy, profit and loss, investment strategy, clinical programs and oversight of manufacturing as well as leading a cross-functional team of internal employees and multiple external consultants.

Medical Device and Biotech strategy consulting. Notable projects:- Business Development and Investment lead for San Diego based infectious disease biotech. Worked with firm leadership and VCs to raise funds for phase III study and eventual commercialization- External BD support for business development and drug delivery team out-license of three diabetes compounds to multi-national pharmaceutical firm for €3.5B- Business development and analytics lead for bankruptcy restructuring of commercial stage biotech; resulted in significant private equity investment

Amylin commercial lead during partnering discussions for OUS rights to $700M assets from AMLN portfolio. Discussions did not result in deal but led to sale of firm for $7.1B in 3Q12. Significant experience presenting to all levels (C-level and BOD) of publicly traded firms.In charge of human factors programs for next generation delivery device in 7 countries. Efforts resulted in significant improvements in usability for device. Summary of 5 year project will be utilized for human factors submission to FDA in the near futureDevice development program lead for multiple programs with sourcing, design and manufacturing in Asia. Unique approach to sourcing resulted in design and pre-production savings in one program of over $2M (75%) with superior quality and timingGlobal Commercial Director for $300M device development program. Business lead on licensing team, managed $20M budget and cross functional teams across 3 continents. Developed global brand and launch plans and associated strategies for assets. In 2010 drove initiative to stop implementation of a clinical trial for next generation delivery device resulting in savings of $6M to firm. Results achieved through working with executive management to communicate significant downsides and limited upside to conduct of trial.Led assessment teams for multiple alternative delivery technologies incorporating both re-formulation and device development. Resulted in increase in overall valuation of portfolio and stoppage of several low value programs.Key liaison with Eli Lilly, Astra Zeneca and BMS Japan affiliates. Resulted in significant increases in trust and communication with affiliates and enhanced development of delivery devices for Asian markets.Coached and developed direct reports and personnel across engineering, device development and marketing functions.

Drove efforts to re-focus global insulins and device businesses. Management of multiple cross functional teams resulted in development of new strategies across the portfolio.Orchestrated development of strategy for medical device group, resulting in new direction and goals. Developed and integrated strategies for drug delivery technologies and life-cycle management. Accountable for multiple corporate strategy projects resulting in new business model experiments and significantly revised commercial targets being implemented.Marketing and commercial lead on over 20 business development negotiations (US, EU, Asia) in multiple therapeutic areas. Formed and led business development market research and forecasting team for 2 years. Resulted in first dedicated market research budget for business development activities.Core member of Lilly Decision Sciences Think Tank. This was a group that consulted at senior levels of the organization regarding portfolio management strategies, decision making methodologies and modeling of issues.Led Drug Delivery Steering Committee, an evaluation group that determined feasibility of new delivery opportunities for business development pursuit. Team also commissioned market research pertaining to new technologies and their potential adoption/need.